Baseline Characteristics for Study Subjects and Controls
| Historical controls (N = 11) | Denosumab subjects (N = 4) | |
| Age (years), mean ± SD3 | 67.8 ± 5.0 | 73.5 ± 3.7 |
| Years since menopause, mean ± SD | 17.7 ± 6.0 | 26.6 ± 7.3 |
| Race, white, n (%) | 10 (90.9) | 4 (100.0) |
| Body mass index (kg/m2), mean ± SD | 29.7 ± 6.0 | 25.2 ± 2.6 |
| Prior fracture, n (%) | 8 (72.7) | 3 (75.0) |
| Hip | 1 (9.1) | 1 (25.0) |
| Spine | 0 (0.0) | 0 (0.0) |
| Wrist | 0 (0.0) | 1 (25.0) |
| Other | 7 (63.6) | 2 (50.0) |
| Prior osteoporosis treatment, n (%) | 8 (72.7) | 4 (100.0) |
| Denosumab | 0 (0.0) | 4 (100.0) |
| Number of doses received, mean ± SD | 0 ± 0.0 | 4 ± 3.4 |
| Bisphosphonates4 | 4 (36.4) | 0 (0.0) |
| Hormone replacement therapy/SERM5 | 5 (45.5) | 0 (0.0) |
| Historical controls (N = 11) | Denosumab subjects (N = 4) | |
| Age (years), mean ± SD3 | 67.8 ± 5.0 | 73.5 ± 3.7 |
| Years since menopause, mean ± SD | 17.7 ± 6.0 | 26.6 ± 7.3 |
| Race, white, n (%) | 10 (90.9) | 4 (100.0) |
| Body mass index (kg/m2), mean ± SD | 29.7 ± 6.0 | 25.2 ± 2.6 |
| Prior fracture, n (%) | 8 (72.7) | 3 (75.0) |
| Hip | 1 (9.1) | 1 (25.0) |
| Spine | 0 (0.0) | 0 (0.0) |
| Wrist | 0 (0.0) | 1 (25.0) |
| Other | 7 (63.6) | 2 (50.0) |
| Prior osteoporosis treatment, n (%) | 8 (72.7) | 4 (100.0) |
| Denosumab | 0 (0.0) | 4 (100.0) |
| Number of doses received, mean ± SD | 0 ± 0.0 | 4 ± 3.4 |
| Bisphosphonates4 | 4 (36.4) | 0 (0.0) |
| Hormone replacement therapy/SERM5 | 5 (45.5) | 0 (0.0) |
N = number of subjects with an evaluable biopsy for fluorochrome labeling; n = number of subjects with observed data; SERM = selective estrogen receptor modulators.
Age at first administration of fluorochrome treatment.
At least 1 year prior to THR.
At least 3 months prior to THR.
Baseline Characteristics for Study Subjects and Controls
| Historical controls (N = 11) | Denosumab subjects (N = 4) | |
| Age (years), mean ± SD3 | 67.8 ± 5.0 | 73.5 ± 3.7 |
| Years since menopause, mean ± SD | 17.7 ± 6.0 | 26.6 ± 7.3 |
| Race, white, n (%) | 10 (90.9) | 4 (100.0) |
| Body mass index (kg/m2), mean ± SD | 29.7 ± 6.0 | 25.2 ± 2.6 |
| Prior fracture, n (%) | 8 (72.7) | 3 (75.0) |
| Hip | 1 (9.1) | 1 (25.0) |
| Spine | 0 (0.0) | 0 (0.0) |
| Wrist | 0 (0.0) | 1 (25.0) |
| Other | 7 (63.6) | 2 (50.0) |
| Prior osteoporosis treatment, n (%) | 8 (72.7) | 4 (100.0) |
| Denosumab | 0 (0.0) | 4 (100.0) |
| Number of doses received, mean ± SD | 0 ± 0.0 | 4 ± 3.4 |
| Bisphosphonates4 | 4 (36.4) | 0 (0.0) |
| Hormone replacement therapy/SERM5 | 5 (45.5) | 0 (0.0) |
| Historical controls (N = 11) | Denosumab subjects (N = 4) | |
| Age (years), mean ± SD3 | 67.8 ± 5.0 | 73.5 ± 3.7 |
| Years since menopause, mean ± SD | 17.7 ± 6.0 | 26.6 ± 7.3 |
| Race, white, n (%) | 10 (90.9) | 4 (100.0) |
| Body mass index (kg/m2), mean ± SD | 29.7 ± 6.0 | 25.2 ± 2.6 |
| Prior fracture, n (%) | 8 (72.7) | 3 (75.0) |
| Hip | 1 (9.1) | 1 (25.0) |
| Spine | 0 (0.0) | 0 (0.0) |
| Wrist | 0 (0.0) | 1 (25.0) |
| Other | 7 (63.6) | 2 (50.0) |
| Prior osteoporosis treatment, n (%) | 8 (72.7) | 4 (100.0) |
| Denosumab | 0 (0.0) | 4 (100.0) |
| Number of doses received, mean ± SD | 0 ± 0.0 | 4 ± 3.4 |
| Bisphosphonates4 | 4 (36.4) | 0 (0.0) |
| Hormone replacement therapy/SERM5 | 5 (45.5) | 0 (0.0) |
N = number of subjects with an evaluable biopsy for fluorochrome labeling; n = number of subjects with observed data; SERM = selective estrogen receptor modulators.
Age at first administration of fluorochrome treatment.
At least 1 year prior to THR.
At least 3 months prior to THR.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
